Articles by Hiromichi Wada

Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases

Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa, et al

Citation: European Cardiology Review 2019;14(2):117–22

DOI:

https://doi.org/10.15420/ecr.2019.17.2
Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine- Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, et al

Citation: European Cardiology Review 2018;13(2):136.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.ER1
Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, et al

Citation: European Cardiology Review 2018;13(2):121.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO2
Relationship Between VEGF-C Levels and Mortality in Patients with Peripheral Artery Disease

Nobutoyo Masunaga, Shuichi Ura, Mitsuru Ishii, et al

Citation: European Cardiology Review 2018;13(2):123.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO4
VEGF-C and Cardiovascular Mortality in Patients Undergoing Drug-eluting Stent Implantation

Takashi Unoki, Shuichi Ura, Daisuke Takagi, et al

Citation: European Cardiology Review 2018;13(2):124.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO5
The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy

Satoshi Shimizu, Yoichi Sunagawa, Kodai Hara, et al

Citation: European Cardiology Review 2018;13(2):125.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO6
TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4

Yasufumi Katanasaka, Masatoshi Namiki, Yoichi Sunagawa, et al

Citation: European Cardiology Review 2018;13(2):126.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO7
Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure

Moritake Iguchi, Shuichi Ura, Nobutoyo Masunaga, et al

Citation: European Cardiology Review 2018;13(2):129.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO10
Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama, Hiromichi Wada, Hajime Yamakage, et al

Citation: European Cardiology Review 2017;12(2):96.

DOI:

https://doi.org/10.15420/ecr.2017:23:5
A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure

Yoichi Sunagawa, Masafumi Funamoto, Anna Suzuki, et al

Citation: European Cardiology Review 2017;12(2):105.

DOI:

https://doi.org/10.15420/ecr.2017:23:14
Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo

Kana Shimizu, Masafumi Funamoto, Mai Genpei, et al

Citation: European Cardiology Review 2017;12(2):106.

DOI:

https://doi.org/10.15420/ecr.2017:23:15
The Inhibitory Effects of Curcumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, et al

Citation: European Cardiology Review 2017;12(2):107.

DOI:

https://doi.org/10.15420/ecr.2017:23:16
A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure

Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, et al

Citation: European Cardiology Review 2017;12(2):110.

DOI:

https://doi.org/10.15420/ecr.2017:23:19
Analysis of Factors Associated with Smoking Relapse

Sayaka Shimada, Maki Komiyama, Hiromichi Wada, et al

Citation: European Cardiology Review 2017;12(2):111.

DOI:

https://doi.org/10.15420/ecr.2017:23:20